Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women

Clinical Therapeutics

Volumn 24, Issue 12, 2002, Pages 2088-2104

  Henry Jr , Dan C ^a   Bettis, Robert B ^b   Riffer, Ernie ^c   Haverstock, Daniel C ^d   Kowalsky, Steven F ^d   Manning, Kathryn ^d   Hamed, Kamal A ^d,e   Church, Deborah A ^d  

^a Foothill Family Clinic   (United States)

^b Edmonds Family Medicine Clinic   (United States)

^c Central Phoenix Medical Clinic   (United States)

^d BAYER CORPORATION   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Ciprofloxacin; Extended release; Once daily; Uncomplicated urinary tract infection

Indexed keywords

CIPROFLOXACIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACKACHE; CLINICAL FEATURE; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSURIA; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; PRURITUS; PYURIA; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE CULTURE; VAGINA CANDIDIASIS; VAGINITIS; VOMITING;

EID: 0036931775     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80099-6     Document Type: Article

References (30)

1. Warren JW, Abrutyn E, Hebel JR, et al, for the Infectious Diseases Society of America (IDSA). Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis. 1999;29:745-758.
2. Barnett BJ, Stephens DS. Urinary tract infection: An overview. Am J Med Sci. 1997;314:245-249.
3. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am. 1997;11:551-581.
4. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med. 2001;135:41-50.
5. Gilbert DN, Moellering RC Jr, Sande MA. The Sanford Guide to Antimicrobial Therapy. 31st Ed. Hyde Park, Vt: Antimicrobial Therapy, Inc; 2001.
6. Cipro Tablets and Cipro 5% and 10% Oral Suspension [Package Inserts]. West Haven, Conn: Bayer Corporation; July 2002.
7. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 5th Ed. Approved Standard. NCCLS document M7-A5. Wayne, Pa: NCCLS; 2000.
8. National Committee for Clinical Laboratory Standards. Performance Standard for Antimicrobial Susceptibility Testing. 10th Informational Supplement (Aerobic Dilution). NCCLS document M100-S10. Wayne, Pa: NCCLS; 2000.
9. Krol GJ, Beck GW, Benham T. HPLC analysis of ciprofloxacin and ciprofloxacin metabolites in body fluids. J Pharm Biomed Anal. 1995;14:181-190.
10. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA. 1999;281:736-738.
11. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: A nationwide analysis. Clin Infect Dis. 2001;33:89-94.
12. Karlowsky JA, Jones ME, Thornsberry C, et al. Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999. Int J Antimicrob Agents. 2001;18:121-127.
13. Gomolin IH, Siami PF, Reuning-Scherer J, et al. Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim-sulfamethoxazole oral suspension for treatment of older women with acute urinary tract infection. J Am Geriatr Soc. 2001;49:1606-1613.
14. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: A randomized trial. JAMA. 2000;283:1583-1590.
15. Masterton RG, Bochsler JA. High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. J Antimicrob Chemother. 1995;35:129-137.
16. McCarty JM, Richard G, Huck W, et al, for the Ciprofloxacin Urinary Tract Infection Group. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Am J Med. 1999;106:292-299.
17. Noskin GA, Zembower T, Chmielewski J, et al. Disappearance of the "uncomplicated" urinary tract infection. Clin Drug Invest. 2001;21(Suppl 1):13-20.
18. Karlowsky JA, Kelly LJ, Thornsberry C, et al. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother. 2002;46:2540-2545.
19. Goettsch W, van Pelt W, Nagelkerke N, et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands. J Antimicrob Chemother. 2000;46:223-228.
20. Kahlmeter G. The ECO*SENS Project: A prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens - Interim report. J Antimicrob Chemother. 2000;46(Suppl 1):15-22.
21. Felmingham D, Arakawa S. Resistance among urinary tract pathogens: Experience outside the USA. Clin Drug Invest. 2001;21(Suppl 1):7-11.
22. Farra A, Skoog G, Wallen L, et al. Antibiotic use and Escherichia coli resistance trends for quinolones and cotrimoxazole in Sweden. Scand J Infect Dis. 2002;34:449-455.
23. Gales AC, Jones RN, Gordon KA, et al. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: Report from the second year of the SENTRY Antimicrobial Surveillance Program (1998). J Antimicrob Chemother. 2000;45:295-303.
24. Iravani A, Tice AD, McCarty J, et al, for the Urinary Tract Infection Study Group. Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women. The minimum effective dose [corrected]. Arch Intern Med. 1995;155:485-494.
25. Iravani A, Klimberg I, Briefer C, et al. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother. 1999;43(Suppl A):67-75.
26. Sahm DF, Thornsberry C, Kelly LJ, et al. In vitro activities of commonly used antibiotics against prevalent uropathogens: Implications for empiric therapy. Infect Urol. 2001;14:59-67.
27. Lagast H, Husson M, Klastersky J. Bactericidal activity of ciprofloxacin in serum and urine against Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus faecalis. J Antimicrob Chemother. 1985;16:341-347.
28. Guan L, Blumenthal RM, Burnham JC. Analysis of macromolecular biosynthesis to define the quinolone-induced postantibiotic effect in Escherichia coli. Antimicrob Agents Chemother. 1992;36:2118-2124.
29. Stass H, Nagelschmitz J, Brendel E, et al. Pharmacokinetic characterization of a new ciprofloxacin once daily formulation for treatment of uncomplicated urinary tract infections. Poster presented at: Meeting of the American Federation for Medical Research; April 11-14, 2002; Baltimore, Md. Poster 24.
30. Naber KG, Theuretzbacher U, Moneva-Koucheva G, Stass H. Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1999;18:783-789.